Founded in 2014 and based in Bangalore, India, BUGWORKS has developed a platform that produces multiple broad-spectrum assets to tackle the problem of AMR, including dual-target antibiotics that cover ESKAPE spectrum of pathogens. The company's platform also has applications in Hospital, Community infections, BioDefense, and Immuno-Oncology. BUGWORKS is currently designing small-molecule Adenosine A2AR/A2BR antagonists, which are being tested as stand-alone and combination therapies for various solid tumors. The company aims to provide affordable and accessible solutions to large unmet needs in AMR and immuno-oncology.